Provided by Tiger Trade Technology Pte. Ltd.

T. Rowe Price Health Care ETF

33.22
-0.1186-0.36%
Post-market: 33.19-0.0277-0.08%16:16 EDT
Volume:3K
Turnover:85.60K
Market Cap:32.39M
PE:- -
High:33.32
Open:33.32
Low:33.08
Close:33.34
52wk High:36.72
52wk Low:27.57
Shares:975.00K
Float Shares:975.00K
Volume Ratio:0.35
T/O Rate:0.26%
Dividend:0.16
Dividend Rate:0.49%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Agilent Technologies Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 22

Moderna Inc. Stock Climbs 12.3%, Outperforms Peers

Dow Jones
·
Sep 22

Sector Update: Healthcare

MT Newswires Live
·
Sep 22

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients taking Foundayo

TIPRANKS
·
Sep 22

Top Midday Stories: Paramount Skydance Settles With US States to Pave Way for Warner Bros. Deal; Anthropic Now Eyeing November IPO

MT Newswires Live
·
Sep 21

Novo Nordisk Says New Obesity Drug Outperformed Lilly's Zepbound in Phase 3 Trial

Dow Jones
·
Sep 21

Novo Stock (NVO) Sinks Despite Beating Eli Lilly in New CagriSema Obesity Trial

TIPRANKS
·
Sep 21

Pharma Sector Doubles Down on AI to Slash Costs, Timelines

Reuters
·
Sep 21

Oura Files for Initial Public Offering on Nasdaq

MT Newswires Live
·
Sep 21

Smart Ring Maker Oura Eyes $15.6 Billion IPO Valuation in Fall Listings Demand Test

Reuters
·
Sep 21

Oura - Eli Lilly Interested in Purchasing up to $100 Mln; Dragoneer up to $300 Mln in IPO - SEC Filing

THOMSON REUTERS
·
Sep 21

Novo Says Its Next-Gen Obesity Drug Tops Lilly Rival in Late-Stage Study

Reuters
·
Sep 21

Eli Lilly, Novo sued over risk of sudden vision loss, WSJ reports

TIPRANKS
·
Sep 20

Leadership Departure and Flawed Compensation Clauses Cast Doubt on Ruifeng's Acquisition Deal

Deep News
·
Sep 20

Retension Pharmaceuticals, TRex Bio File for US IPO as Biotech Momentum Continues

Reuters
·
Sep 19

Steris PLC Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 19

Sector Update: Healthcare

MT Newswires Live
·
Sep 19

Eli Lilly reports full FDA approval of Inluriyo combo for certain breast cancers

TIPRANKS
·
Sep 19

US FDA Approves Lilly Inluriyo-Verzenio Combo for ESR1-Mutated Metastatic Breast Cancer

Reuters
·
Sep 19

U.S. FDA Approves Inluriyo (Imlunestrant) in Combination with Verzenio (Abemaciclib) for Adults with Er+, Her2-, Esr1-Mutated Advanced or Metastatic Breast Cancer

THOMSON REUTERS
·
Sep 19